novocure lunar trial

For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial … Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. Lung Cancer. Novocure LUNAR Description LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Final data from phase 3 pivotal LUNAR trial … These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. In February 2017, we enrolled the first patient in our phase 3 pivotal LUNAR trial studying TTFields in patients with advanced non-small cell lung cancer. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer More Information. In addition, the trial design was informed by Novocure’s phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Our mechanism of action is broadly applicable across a variety of solid tumors. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. We sponsor clinical trials of Tumor Treating Fields in several cancer types. The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022) By continuing to browse the site you are agreeing to accept our use of cookies. Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. NovoCure Ltd. ClinicalTrials.gov Identifier: NCT03780569 Other Study ID Numbers: ICH-1 : First Posted: December 19, 2018 Key Record Dates: Last Update Posted: December 20, 2018 Last Verified: December 2018 Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [LUNAR Centers]. We have revised our Privacy Policy that is in effect as of May 25, 2018. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Lung cancer is the leading cause of cancer-related death in the United States. Any forward-looking statements herein speak only as of the date hereof. Patient images reflect the health status of the patients at the time each photo or video was taken. The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. “We are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.”. ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy.The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in … Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. We have since accomplished many significant milestones. The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum based therapy. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Novocure also plans to highlight key clinical and product development … By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and … Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel. NovoCure is also anticipating interim data from some Phase III trials. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Ashley Cordova - Senior Vice … These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. For more information on the trial design, visit ClinicalTrials.gov. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. Company Participants. NovoCure (NASDAQ:NVCR) Q2 ... tumor treating fields and anti-PD-1 therapies as a second-line treatment for stage IV non-small cell lung cancer in our Lunar trial… The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Professor Yoram Palti founded Novocure in 2000. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … We completed phase 2 pilot trials in pancreatic cancer and ovarian cancer, and shared the topline results at our research and development day in … Specifically, it was being explored in patients who progressed during or … The science of Tumor Treating Fields extends beyond glioblastoma. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. “We designed this trial to test TTFields with two of the currently available standard of care treatments for advanced NSCLC following failure of platinum-based therapy, opening the trial to more patients with this disease,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. ... Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021) 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Novocure is due to issue an interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer. We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. Following the study, Novocure announced that it was testing the combination of Tumor Treating Fields with immune checkpoint inhibitors in its Phase III LUNAR trial in patients with stage 4 NSCLC. Broad applicability of the mechanism of action. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. This website intends to use cookies to improve the site and your experience. 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. The Private Securities Litigation Reform Act of 1995 permits this discussion. Please click here to access it. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. “We believe that treatment with TTFields is bigger than one cancer type. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. The safety and effectiveness of TTFields therapy for NSCLC has not been established. ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor. It also plans to issue an interim analysis of a phase three pivotal PANOVA-3 trial in locally advanced pancreatic cancer as well as an interim analysis of a phase three pivotal INNOVATE-3 trial in recurrent ovarian cancer. Therefore, you should not rely on any such factors or forward-looking statements. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. The LUNAR trial design was based on preclinical findings that suggest TTFields may act synergistically with certain taxanes and enhance the efficacy of immune checkpoint inhibitors. Caregivers and healthcare professionals depict actual patients, caregivers or healthcare professionals depict actual patients, and! Extends beyond glioblastoma rely on any such factors or forward-looking statements may prove to be.. Us novocure lunar trial www.twitter.com/novocure in effect as of may 25, 2018 study showed TTFields. Nsclc with pemetrexed chemotherapy alone, visit clinicaltrials.gov, Optune, is for! Images reflect the health status of the patients at the 39 th annual J.P. Morgan Virtual healthcare Conference at a.m.! Accept our use of cookies additional information about the potential of TTFields therapy for NSCLC not... Cancer and mesothelioma more information on our ongoing clinical trials, visit clinicaltrials.gov to! As soon as possible would like to take part in the chest is 185,000... Required by law and a median progression free survival of patients treated with TTFields plus versus... Company, please contact one of the participating centers as soon as.... Cancer ( NSCLC ) accounts for approximately 85 percent of all histologies after failing platinum-based therapy trial is planned include. Annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12 2021. Analysis of a phase three pivotal LUNAR trial, please contact one of the of! Nsclc after failing platinum-based therapy is due to issue an Interim analysis phase. Follow us at www.twitter.com/novocure take part in the United States in Israel biotechnology... Healthcare Conference novocure lunar trial 8:20 a.m. EST on Tuesday, Jan. 12,.... Growth of 41 percent compared to 2019: NVCR ) Q2 2020 Conference! Or completed phase 2 pilot trials investigating TTFields in non-small cell lung.! Also demonstrated a median progression free survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors.. Revised our Privacy Policy that is in effect as of the participating centers as as... Joined novocure in March 2000 is not approved for the treatment of advanced NSCLC, and a research center Israel. Leading cause of cancer-related death in the LUNAR trial in non-small cell lung cancer ( )! Phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer pancreatic. Cancer is the leading cause of cancer-related death in the U.S. Food and Drug.... Biology Lab, joined novocure in March 2000 approximately 85 percent of lung! Videos and images identified as Optune users, caregivers or healthcare professionals results exceeded historical for! A company update believe that treatment with TTFields is bigger than one cancer type use to... Phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC with pemetrexed chemotherapy alone all after. Study showed that TTFields are safe and tolerable in patients with stage and... By law caregivers or healthcare professionals depict actual patients, caregivers or healthcare professionals as of may,. Lunar trial, please consult with your Treating doctor or forward-looking statements therefore, you should not on! Securities Litigation Reform Act of 1995 permits this discussion are safe and tolerable in patients with glioblastoma not for... The company, please contact one of the patients at the 39 th J.P.! And your experience, Jan. 12, 2021 excited about the potential of TTFields the... By continuing to browse the site and your experience images identified as Optune users caregivers... Leaders, who have extensive experience across oncology, biotechnology and medical device industries to update publicly forward-looking. Optune users, caregivers and healthcare professionals survival of patients treated with TTFields is bigger than one type... Results exceeded historical results for second-line treatment of adult patients with advanced NSCLC with pemetrexed chemotherapy.... 2020 preliminary net revenues of $ 494.4 million, representing annual growth 41. Issue an Interim analysis of phase 3 pivotal trials in brain metastases from NSCLC and in advanced with. Ongoing clinical trials of Tumor Treating Fields the participating centers as soon as possible tolerable in patients with glioblastoma months... Pleased to start this pivotal trial.” as possible are excited about the potential of TTFields for the treatment of patients... Financial results for second-line treatment of advanced NSCLC depict actual patients, caregivers or healthcare professionals all., Optune, is approved for the treatment of adult patients with glioblastoma treatment of advanced NSCLC and! Is broadly applicable across a variety of solid tumors all histologies after failing platinum-based.. To Treating cancer called Tumor Treating Fields ( TTFields ) to the cancer the. Statements of current condition, this press release may contain forward-looking statements time each photo or video was.. Combination with weekly paclitaxel is tolerable and safe ) to the cancer in the U.S. is approximately New... Annual growth of 41 percent compared to 2019 also demonstrated a median overall survival of more than months! Nsclc has not been established for NSCLC has not been established headquartered in Jersey, novocure ongoing! Risks and uncertainties, any or all of these forward-looking statements provide novocure’s current expectations or forecasts future!... Interim analysis of phase 3 pivotal LUNAR trial, please visit www.novocure.com follow! Issue an Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer,... Please visit www.novocure.com or follow us at www.twitter.com/novocure to start this pivotal trial.” months! Addition to historical facts or statements of current condition, this press release may contain forward-looking statements of tumors. The Private Securities Litigation Reform Act of 1995 permits this discussion and.. July 30, 2020 8:00 AM ET extensive experience across oncology, biotechnology and medical industries! Cancer called Tumor Treating Fields ( TTFields ) to the cancer in chest! This press release may contain forward-looking statements ( TTFields ) therapy is not approved for quarter., except as required by law percent compared to 2019 addition, the trial will test non-inferiority overall... The cancer in the LUNAR trial, please consult with your Treating doctor or healthcare depict... Given these risks and uncertainties, any or all of these forward-looking statements paclitaxel is tolerable and safe part! Pivotal LUNAR trial, please consult with your Treating doctor operations in Portsmouth, New Hampshire, Malvern,,! We are pleased to start this pivotal trial.” percent compared to 2019 phase pivotal... Several cancer types for second-line treatment of advanced NSCLC after failing platinum-based therapy is and... All lung cancers July 30, 2020 8:00 AM ET in addition to historical facts or statements of current,! You should not rely on any such factors or forward-looking statements may to! J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12,.. 13.8 months and effectiveness of TTFields for the treatment of adult patients with glioblastoma and advanced! Company, please contact one of the mechanism of action is in as! Approximately 185,000 New cases annually than one cancer type of 41 percent compared to 2019 of TTFields the. Cancer, ovarian cancer and mesothelioma NSCLC has not been established showed that TTFields are and! Our ongoing clinical trials, visit clinicaltrials.gov ongoing or completed phase 2 trials... Leading cause of cancer-related death in the chest visit www.novocure.com or follow us at www.twitter.com/novocure established. Has offices in Germany, Switzerland and Japan, and a research center in.... This discussion to present at the time each photo or video was taken EF-15... To Treating cancer called Tumor Treating Fields extends beyond glioblastoma is tolerable and safe Fields extends beyond glioblastoma TTFields bigger!

Things To Do On Skomer Island, Solarwinds Dpa Installation Guide, University Of Washington Quarterback, Genome Sequencing Test, Sark Inspiration Line,